Erratum: The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies (Clinical Pharmacology and Therapeutics (2008) 84 (417-423) DOI: 10.1038/clpt.2008.141);The role of ethnicity in variability in response to drugs: Focus on clinical pharmacology studies

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 3, 2008, Pages 417-423

  Yasuda, S U ^a   Zhang, L ^a   Huang, S M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ATOMOXETINE; BREAST CANCER RESISTANCE PROTEIN; CODEINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; DIAZEPAM; DRUG METABOLIZING ENZYME; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B7; METHADONE; MULTIDRUG RESISTANCE PROTEIN 1; NEVIRAPINE; NICOTINE; OMEPRAZOLE; PACLITAXEL; PHENYTOIN; REPAGLINIDE; TACROLIMUS; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

CLINICAL PHARMACOLOGY; CONTINUING EDUCATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG USE; ETHNIC DIFFERENCE; ETHNICITY; FOOD AND DRUG ADMINISTRATION; GRAFT REJECTION; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

EID: 49949090275     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.174     Document Type: Erratum

References (37)

1. Andersson, T. et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin. Pharmacol. Ther. 78, 559-581 (2005).
2. Huang, S.M., Temple, R., Throckmorton, D.C. & Lesko, L.J. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther. 81, 298-304 (2007).
3. Bjornsson, T.D. et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31, 815-832 (2003).
4. Williams, J.A. et al. PhRMA White Paper on ADME Pharmacogenomics. J. Clin. Pharmacol. 48, 849-889 (2008).
5. Roy, J.N. et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 33, 884-887 (2005).
6. Prograf [package insert]. Deerfield, IL, Astellas Pharma US, 2006.
7. Mancinelli, L.M. et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin. Pharmacol. Ther. 69, 24-31 (2001).
8. Vadivel, N., Garg, A., Holt, D.W., Chang, R.W.S. & MacPhee, I.A.M. Tacrolimus dose in black renal transplant recipients. Transplantation 83, 997-999 (2007).
9. Crestor [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals, 2005.
10. Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78, 330-341 (2005).
11. Kim, K.T., Birmingham, C.T., Azumaya, C.T., Chen, Y., Schneck, D. & Zalikowski, J. Increased systemic exposure to rosuvastatin in Asian subjects residing in the United States compared to Caucasian subjects. Clin. Pharmacol. Ther. 83 (suppl. 1), S14 (2008).
12. Limdi, N.A. et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol. Ther. 83, 312-321 (2008).
13. Yuan, H.-Y. et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Human Hol. Genet. 14, 1745-1751 (2005).
14. Hung, S.I. et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16, 297-306 (2006).
15. Chung, W.H. et al. A marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
16. Nakajima, M. et al. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin. Pharmacol. Ther. 80, 282-297 (2006).
17. Schoedel, K.A., Hoffman, E.B., Rao, Y., Sellers, E.M. & Tyndale, R.F. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14, 615-626 (2004).
18. Lang, T. et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11, 399-415 (2001).
19. Kirchheiner, J. et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13, 619-626 (2003).
20. Klein, K. et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15, 861-873 (2005).
21. Nakajima, M. et al. Genetic polymorphisms of CYP2C8 in Japanese population. Drug Metab. Dispos. 31, 687-690 (2003).
22. Garcia-Martin, E., Martinez, C., Ladero, J.M. & AGundez, J.A. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol. Diagn. Ther. 10, 29-40 (2006).
23. Bjornsson, T.D. et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J. Clin. Pharmacol. 43, 943-967 (2003).
24. Myrand, S.P. et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin. Pharmacol. Ther., this issue.
25. Bernard, S., Neville, K.A., Nguyen, A.T. & Flockhart, D.A. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 11, 126-135 (2006).
26. Kroetz, D.L. et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 13, 481-94 (2003).
27. Zamber, C.P. et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 13, 19-28 (2003).
28. Pasanen, M.K., Backman, J.T., Neuvonen, P.J. & Niemi, M. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 62, 409-415 (2006).
29. Ho, R.H. et al. Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet. Genomics 17, 647-656 (2007).
30. König, J., Seithel, A., Gradhand, U. & Fromm, M.E. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 372, 432-443 (2006).
31. Xu, L.Y. et al. Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta Pharmacol. Sin. 28, 1693-1697 (2007).
32. Kim, S.R. et al. Genetic variations and frequencies of major haplotypes in SLC01B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15. Drug Metab. Pharmacokinet. 22, 456-461 (2007)
33. Ando, Y., Fujita, K., Sasaki, Y. & Hasegawa, Y. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Curr. Opin. Mol. Ther. 9, 258-262 (2007).
34. Liu, J.Y., Qu, K., Sferruzza, A.D. & Bender, R.A. Distribution of the UGT1A1*28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals. Anticancer Drugs 18, 693-696 (2007).
35. Kaniwa, N. et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab. Dispos. 33, 458-465 (2005).
36. Bhasker, C.R. et al. Genetic polymorphism of UDP- glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10, 679-685 (2000).
37. Larramendy-Gozalo, C. et al. Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population. Basic Clin. Pharmacol. Toxicol. 98, 611-613 (2006).